We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amedisys Gains on Expanding Hospice Arm, Favorable Demography
Read MoreHide Full Article
On Apr 14, we issued an updated research report on Amedisys, Inc. (AMED - Free Report) . The stock currently carries a Zacks Rank #2 (Buy).
This renowned home health and hospice services provider has outperformed its industry over the past three months. The stock has rallied 48.2%, as against the 0.4% loss of the industry.
At the Home Health and Hospice divisions, the company witnessed stellar growth in Medicare and non-Medicare revenues during fourth-quarter 2019. In Hospice, as a major breakthrough, the company topped the national average in all measurement categories during the quarter and is presently positioned as the top national player.
Amedisys is currently exploring opportunities in the Home Health and Hospice segments. The company has been benefiting from the recent acquisitions of hospice care providers — RoseRock Healthcare and Compassionate Care Hospice (CCH). Amedisys’ ADC (average daily census) rose 8% and same-store admissions increased 4% during the December-end quarter. The company’s solid performance in the recently-launched Personal Care segment has also driven its stock-price rally.
Amedisys is currently focused on improving its clinical quality. In this regard, we take note that the company’s current Quality of Patient Care Star QPC score was 4.26. It now has 15% of its care centers rated at 5 stars, with 91% of overall portfolio rated at 4 stars or better. Amedisys is targeting to achieve a 4.0 Quality Star Rating for all its care centers. In Hospice, as a major breakthrough, during the fourth quarter as well, the company topped the national average in all measurement categories and is positioned as the top national player, at present.
Meanwhile, the company is poised to benefit from the aging demographics of the U.S. population and the need for higher acuity patients in a home-nursing environment. Also, Amedisys’ strong cash balance bolsters investor confidence in the stock.
However, elevated operating expenses and a declining gross margin continue to raise concerns. Further, an intensely competitive landscape and regulatory woes weigh on the home health and hospice industry.
DexCom’s long-term earnings growth rate is estimated at 36.7%. The company presently holds a Zacks Rank #2.
Surmodics’ long-term earnings growth rate is projected at 10%. It currently carries a Zacks Rank #2.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
Amedisys Gains on Expanding Hospice Arm, Favorable Demography
On Apr 14, we issued an updated research report on Amedisys, Inc. (AMED - Free Report) . The stock currently carries a Zacks Rank #2 (Buy).
This renowned home health and hospice services provider has outperformed its industry over the past three months. The stock has rallied 48.2%, as against the 0.4% loss of the industry.
At the Home Health and Hospice divisions, the company witnessed stellar growth in Medicare and non-Medicare revenues during fourth-quarter 2019. In Hospice, as a major breakthrough, the company topped the national average in all measurement categories during the quarter and is presently positioned as the top national player.
Amedisys is currently exploring opportunities in the Home Health and Hospice segments. The company has been benefiting from the recent acquisitions of hospice care providers — RoseRock Healthcare and Compassionate Care Hospice (CCH). Amedisys’ ADC (average daily census) rose 8% and same-store admissions increased 4% during the December-end quarter. The company’s solid performance in the recently-launched Personal Care segment has also driven its stock-price rally.
Amedisys, Inc. Price
Amedisys, Inc. price | Amedisys, Inc. Quote
Amedisys is currently focused on improving its clinical quality. In this regard, we take note that the company’s current Quality of Patient Care Star QPC score was 4.26. It now has 15% of its care centers rated at 5 stars, with 91% of overall portfolio rated at 4 stars or better. Amedisys is targeting to achieve a 4.0 Quality Star Rating for all its care centers. In Hospice, as a major breakthrough, during the fourth quarter as well, the company topped the national average in all measurement categories and is positioned as the top national player, at present.
Meanwhile, the company is poised to benefit from the aging demographics of the U.S. population and the need for higher acuity patients in a home-nursing environment. Also, Amedisys’ strong cash balance bolsters investor confidence in the stock.
However, elevated operating expenses and a declining gross margin continue to raise concerns. Further, an intensely competitive landscape and regulatory woes weigh on the home health and hospice industry.
Other Key Picks
A few other top-ranked stocks from the broader medical space are ResMed Inc. (RMD - Free Report) , DexCom (DXCM - Free Report) and Surmodics (SRDX - Free Report) .
ResMed has a projected long-term earnings growth rate of 12%. It currently carries a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DexCom’s long-term earnings growth rate is estimated at 36.7%. The company presently holds a Zacks Rank #2.
Surmodics’ long-term earnings growth rate is projected at 10%. It currently carries a Zacks Rank #2.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>